Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL19100314 | 1.00 | GLRA1 (0.91) | — | |
| Glycine SCHEMBL5163283 | 0.96 | GLRA1 (0.83) | — | |
| Glycine SCHEMBL3863155 | 0.96 | — | — | |
| Glycine SCHEMBL4940394 | 0.96 | — | — | |
| Glycine SCHEMBL28123992 | 0.96 | — | — | |
| Glycine SCHEMBL3640989 | 0.95 | GLRA1 (1.00) | — | |
| Glycine SCHEMBL2116443 | 0.95 | — | — | |
| Glycine SCHEMBL391786 | 0.95 | GLRA1 (1.00) | — | |
| Glycine SCHEMBL93765 | 0.95 | GLRA1 (1.00) | — | |
| Glycine SCHEMBL391027 | 0.95 | GLRA1 (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479778-B2 | Plant food to enhance the nutritional value of pollen and nectar of plants to attract bees, butterflies and other pollinators | MAIWALD DIANE (US) | 2025-11-25 | — | — | US | claimed |
| US-20250268950-A1 | PRENATAL SUPPLEMENT | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2025-08-28 | — | — | US | claimed |
| US-20250177457-A1 | SUPPLEMENT COMPOSITION FOR CONSUMPTION BY INDIVIDUALS BEING ADMINISTERED A GLP-1 AGONIST | Food Sciences Corp. | 2025-06-05 | — | — | US | claimed |
| EP-3400260-B2 | SCAVENGER COMPOSITIONS FOR SULFUR SPECIES | INNOPHOS INC (US) | 2025-03-19 | — | — | EP | claimed |
| WO-2025035032-A2 | METHODS AND COMPOSITIONS FOR PROVIDING CUSTOMIZED NUTRITIONAL SUPPLEMENTS | VIBRANT HOLDINGS, LLC (US) | 2025-02-13 | — | — | WO | claimed |
| US-20240390414-A1 | USE OF SODIUM THIOSULFATE (STS) WITH AND WITHOUT COFACTORS FOR THE TREATMENT OF INFLAMMATORY, NEURODEGENERATIVE AND NEUROPSYCHIATRIC CONDITIONS | Thiogenics LLC | 2024-11-28 | — | — | US | claimed |
| CN-118496683-A | Scavenger composition for sulfur species | 伊诺弗斯公司 | 2024-08-16 | — | — | CN | claimed |
| CN-116549462-A | Composition for improving sleep quality and application thereof | 湖南微木生物科技有限公司 | 2023-08-08 | — | — | CN | claimed |
| WO-2023064399-A1 | PRENATAL SUPPLEMENT | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-04-20 | — | — | WO | claimed |
| US-20230009798-A1 | SILICONE IMPLANT ADJUNCT FORMULATIONS AND METHODS OF USE | SUSSE KAYTE R (US) | 2023-01-12 | — | — | US | claimed |
| CN-1477959-A | Compositions and methods for reducing plasma lipoprotein and risk factors for cardiovascular disease | — | 2004-02-25 | — | — | CN | claimed |
| US-6693129-B2 | A BIOCHEMICAL FORMULATION COMPRISING ASCORBIC ACID, NIACIN, LYSINE, AND PROLINE USEFUL FOR LOWERING PLASMA CONCENTRATION OF A LIPOPROTEIN IN MAMMAL | Rath, Matthias | 2004-02-17 | — | — | US | claimed |
| US-6686340-B2 | ADMINISTERING A VITAMIN (ASCORBIC ACID), AN AMINO ACID (ARGININE) AND A TRACE ELEMENT (MAGNESIUM) FOR TREATMENT OF HIGH BLOOD PRESSURE, ASTHMA, GLAUCOMA AND TINNITUS | Rath, Matthias | 2004-02-03 | — | — | US | claimed |
| US-20030211172-A1 | Composition and method for substantially reducing the deleterious effects of alcohol on the body | JONES JEREMY PARK (US) | 2003-11-13 | — | — | US | claimed |
| EP-1324753-A2 | COMPOSITIONS AND METHODS FOR LOWERING PLASMA LIPOPROTEIN(A) AND RISK FACTORS OF CARDIOVASCULAR DISEASES | Rath, Matthias (US) | 2003-07-09 | — | — | EP | claimed |
| US-20030003162-A1 | Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells | RATH MATTHIAS (US) | 2003-01-02 | — | — | US | claimed |
| US-20020094996-A1 | Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases | RATH MATTHIAS (NL) | 2002-07-18 | — | — | US | claimed |
| WO-2002028379-A2 | COMPOSITIONS AND METHODS FOR LOWERING PLASMA LIPOPROTEIN(A) AND RISK FACTORS OF CARDIOVASCULAR DISEASES | RATH MATTHIAS (US) | 2002-04-11 | — | — | WO | claimed |
| CN-1333020-A | Biochemical substance as composition for preventing and treating health-affecting diseases caused by smooth muscle cell contraction in human organs | MASERS LAS (US) | 2002-01-30 | — | — | CN | claimed |
| EP-1163904-A1 | Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium | Rath, Matthias, Dr. med. (NL) | 2001-12-19 | — | — | EP | claimed |